A panel of experts from 11 Spanish-speaking countries publishes the first recommendations tailored to Latin American resources for early-stage hormone receptor-positive, HER2-negative breast cancer....
In the phase III PEARL trial, combining palbociclib with endocrine therapy did not improve progression-free survival versus capecitabine, although it offered a better safety profile and quality of lif...